Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsar-TAD trial of valsartan for heritable thoracic aortic disease
2024-515059-39-00Phase 3Authorised
- Sponsor
- Medical University of Gdańsk
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Marfan syndrome (MFS) and Familial aortopathies (h-TAAD) comparing Valsartan with Placebo (2 arms). Primary endpoint: Absolute annual change in aortic root diameter by transthoracic echocardiography. Planned start Feb 2024; status: authorised.
02
Drugs
valsartan
03
Conditions
Marfan syndrome (MFS)Familial aortopathies (h-TAAD)
Beyond the preview
Go deeper on 2024-515059-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515059-39-00.